Skip to content

Multimodal Model-Based System for Differentiating Benign and Malignant Solid Pancreatic Lesions Under Endoscopic Ultrasound

Multimodal Model-Based System for Differentiating Benign and Malignant Solid Pancreatic Lesions Under Endoscopic Ultrasound

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106293
Enrollment
Unknown
Registered
2025-07-22
Start date
2025-07-31
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Pancreatic Lesions

Interventions

Gold Standard:Benign and malignant solid pancreatic lesions were differentiated using pathological diagnosis and follow-up outcomes as the gold standard.
Index test:A Multimodal Model-Based System for Differentiating Benign and Malignant Solid Pancreatic Lesions under Endoscopic Ultrasound

Sponsors

Renmin Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged >=18 years; 2. Patients with solid pancreatic lesions requiring endoscopic ultrasound (EUS) examination; 3. Patients with the ability to read, understand, and sign the informed consent form; 4. Patients who, in the opinion of the investigators, are able to understand the procedures of this clinical study and are willing and able to comply with and complete all study-related procedures.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women; 2. History of drug or alcohol abuse, or psychiatric disorders within the past five years; 3. Patients with absolute contraindications to endoscopic ultrasound (EUS) examination; 4. Anatomical abnormalities of the upper gastrointestinal tract caused by advanced malignancies; 5. Known acute and severe pharyngeal diseases preventing endoscope insertion; 6. Patients with upper gastrointestinal obstruction; 7. History of allergy to anesthesia; 8. Patients with dysfunction of vital organs such as the heart or lungs; 9. Patients with uncontrolled hypertension; 10. Patients who are unable to cooperate with or complete the EUS examination for any other reason.

Design outcomes

Primary

MeasureTime frame
Accuracy of Differentiating Benign and Malignant Solid Pancreatic Lesions;

Secondary

MeasureTime frame
Sensitivity of Differentiating Benign and Malignant Solid Pancreatic Lesions;Specificity of Differentiating Benign and Malignant Solid Pancreatic Lesions;

Countries

China

Contacts

Public ContactYu Honggang

Renmin Hospital of Wuhan University

yuhonggang1968@163.com+86 138 7128 1899

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026